In Annals of Oncology, genomic characterization 🧬of HR+ breast cancer in very young women enrolled in SOFT shed light on unfavourable prognostic features potentially informing future therapeutic strategies annalsofoncology.org/article/S0923-… Sherene Loi, MD ETOP IBCSG Partners Foundation #bcsm

One of the best things about a career as a scientist are the friends you make along the way. Two months ago I lost an old & dear scientific scientific friend, Al Reynolds. Its great to see his trainees & colleagues share their reminiscences 1/n rupress.org/jcb/article-pd…

We have a new proposed system for assigning "common names" to variants that are being discussed. Nicknames will be based on astronomy. Starting letter indicates lineage/genetic background, a letter "R" in the name shows recombinant ancestry. 1/ whn.global/common-names-f…

Research Opportunity for Neurofibromatosis patients ages 25+ and family caregivers of ages 18-25 currently living in the US. This is a 60-minute web-assisted phone interview. Compensation is $120. #nf #nf1 #nf2 #neurofibromatosis #endnf #nfaware #nfswn bit.ly/rpvnf

linkedin.com/posts/activity…

linkedin.com/posts/activity…

a timeline of artificial intelligence in biomedicine h/t Amee Kapadia

I've updated my list of recommended resources to learn about and keep up to date with the biotech industry. I want this to be the most useful aggregation of relevant resources on the internet, anything I'm missing that I should have included? atelfo.github.io/2022/03/19/the…

🚨 BREAKING NEWS! 🇬🇧 inventor Carol Robinson wins the Lifetime Achievement prize at the European #InventorAward 2024! Her pioneering work in mass spectrometry have transformed our understanding of science. 🏆 Discover her work: bit.ly/CarolVRobinson Oxford University Innovation OMass Therapeutics

It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to? We need to cap these costs for patients and #fixinsurance. Please share and help, Mariah Carey , Jessica Alba, Marshall Mathers, P!nk, Jerome Bettis!

Really pleased that OMass Therapeutics was selected as a Fierce 15 company this year! Thank you FierceBiotech for the recognition and thank you NYSE 🏛 for acknowledging this achievement.

The late great Anthony Bourdain, quote about Chicago. #ChicagoHistory ☑️

I would wish for Aaron to hear the story of how we cured HepC. This happens in many drug classes. There is definitely competition in pharma. nopatientleftbehind.docsend.com/view/veiybp52r… More super wonky learning material at patientleftbehind.org

Our Director of Clinical Operations Angela will be heading to New Brunswick, NJ to attend the CARES Foundation 2024 Annual CAH Education Conference, an event connecting industry and medical experts with individuals affected by congenital adrenal hyperplasia (CAH).

We are delighted to announce three key #appointments to our development team based in the US and UK. Steve Griffen joins as VP of Clinical Development, Angela joins as Director of Clinical Operations & Stuart Hadley joins as Senior Director of CMC. omass.com/2024/10/01/oma…

Elon Musk Elon Musk maybe DOGE can look into efficiencies created by the USPS patent using blockchain for voting, why this is not implemented, and with the savings restore FEHA benefits to USPS. patentimages.storage.googleapis.com/41/07/09/647d1…

Our CEO @RosDeegan was this year’s Women-Led Business Leader of the Year at the European Lifestars Awards! Under Ros’ leadership, we are excited to see what the next year holds! #awards #drugdiscovery #masspec #biotech #lifescience #innovation #leadership

Steven’s presentation, titled ‘Optimising Binding Kinetics Yields Insurmountable MC2 Receptor Antagonists for the Treatment of Diseases of ACTH Excess’ will take place at 4pm GMT on 27th November at 15Hatfields. For more information, visit: gpcrs-europe.com/speaker/steven…

Chicago’s quantum computing ambitions featured in this morning’s The Wall Street Journal